Trehalose for Neurodegenerative Diseases

Migration, Crosslink

📖

Trehalose for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-trehalose-neurodegener

📖 Wiki Page

therapeutic1790 wordssynced 2026-04-02

Trehalose for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Trehalose for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Protein stabilizer</td>
<td>Preferential hydration</td>
</tr>
<tr>
<td class="label">Anti-aggregation</td>
<td>Vitrification</td>
</tr>
<tr>
<td class="label">Chemical chaperone</td>
<td>Folding assistance</td>
</tr>
<tr>
<td class="label">Osmolyte</td>
<td>Volume exclusion</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">IND status</td>
<td>Investigational for neurodegenerative indications</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Oral solution, intravenous</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral preferred for chronic treatment</td>
</tr>
<tr>
<td class="label">Dose in trials</td>
<td>10-100 mg/kg daily</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">NCT05119283</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">NCT04644081</td>
<td>Alzheimer's</td>
</tr>
<tr>
<td class="label">NCT04534478</td>
<td>Parkinson's</td>
</tr>
<tr>
<td class="label">NCT04833638</td>
<td>CBD</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>~30-40%</td>
</tr>
<tr>
<td class="label">Time t

...

Trehalose for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Trehalose for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Protein stabilizer</td>
<td>Preferential hydration</td>
</tr>
<tr>
<td class="label">Anti-aggregation</td>
<td>Vitrification</td>
</tr>
<tr>
<td class="label">Chemical chaperone</td>
<td>Folding assistance</td>
</tr>
<tr>
<td class="label">Osmolyte</td>
<td>Volume exclusion</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">IND status</td>
<td>Investigational for neurodegenerative indications</td>
</tr>
<tr>
<td class="label">Formulation</td>
<td>Oral solution, intravenous</td>
</tr>
<tr>
<td class="label">Route</td>
<td>Oral preferred for chronic treatment</td>
</tr>
<tr>
<td class="label">Dose in trials</td>
<td>10-100 mg/kg daily</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">NCT05119283</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">NCT04644081</td>
<td>Alzheimer's</td>
</tr>
<tr>
<td class="label">NCT04534478</td>
<td>Parkinson's</td>
</tr>
<tr>
<td class="label">NCT04833638</td>
<td>CBD</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Oral bioavailability</td>
<td>~30-40%</td>
</tr>
<tr>
<td class="label">Time to peak (oral)</td>
<td>1-2 hours</td>
</tr>
<tr>
<td class="label">Volume of distribution</td>
<td>~0.5 L/kg</td>
</tr>
<tr>
<td class="label">[Blood-brain barrier](/entities/blood-brain-barrier) penetration</td>
<td>Demonstrated in animal models</td>
</tr>
<tr>
<td class="label">Brain concentration</td>
<td>~10-15% of plasma levels</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">Riluzole + Trehalose</td>
<td>Complementary mechanisms</td>
</tr>
<tr>
<td class="label">Trehalose + Rapamycin</td>
<td>Dual autophagy activation</td>
</tr>
<tr>
<td class="label">Trehalose + Lithium</td>
<td>autophagy + GSK3β inhibition</td>
</tr>
<tr>
<td class="label">Trehalose + Antioxidants</td>
<td>Multiple protective pathways</td>
</tr>
</table>

Trehalose For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Mermaid diagram (expand to render)

Trehalose (alpha-D-glucopyranosyl-(1->1)-alpha-D-glucopyranoside) is a natural disaccharide composed of two glucose molecules linked by an alpha,alpha-1,1-glycosidic bond. Found naturally in various organisms including bacteria, yeast, insects, and some plants, trehalose serves as a protectant against environmental stresses including dehydration, freezing, and heat. This remarkable molecule has garnered significant attention in neurodegeneration research due to its ability to induce autophagy, stabilize proteins, and protect against various forms of cellular stress. [@liu2011]

Unlike sucrose or maltose, trehalose possesses unique biochemical properties that make it particularly valuable as a therapeutic agent. It is a non-reducing sugar, meaning it does not undergo Maillard reactions with proteins, and it has exceptional protein-stabilizing capabilities due to its ability to form a glass-like matrix (vitrification) that preserves protein structure during drying or freezing. These properties have made trehalose extensively used in food preservation and cryopreservation, and now increasingly in biomedical applications for neurodegenerative diseases. [@du2013]

Mechanism of Action

Autophagy Induction

The primary neuroprotective mechanism of trehalose is through induction of autophagy—a cellular process that degrades and recycles damaged organelles, protein aggregates, and intracellular pathogens. Trehalose activates autophagy through multiple overlapping pathways: [@tengesdal2019]

mTOR-Independent Autophagy Activation

Unlike rapamycin which inhibits [mTOR](/entities/mtor), trehalose activates autophagy through a distinct mTOR-independent pathway: [@tanaka2004]

cAMP-PKA pathway modulation: Trehalose elevates intracellular cAMP levels, which through PKA activation promotes autophagy initiation

AMPK activation: Trehalose activates AMP-activated protein kinase (AMPK), the cellular energy sensor that triggers catabolic processes when ATP is low

Intracellular calcium mobilization: Moderate calcium release from endoplasmic reticulum stores activates calmodulin-dependent kinases that promote autophagy

TFEB Activation

Trehalose promotes nuclear translocation of transcription factor EB (TFEB), the master regulator of lysosomal biogenesis and autophagy: [@zhang2014]

[TFEB](/entities/tfeb) target genes: Activates genes encoding lysosomal enzymes (cathepsins), autophagy proteins (LC3, Atg5), and membrane proteins (V-ATPase)
Lysosomal enhancement: Increases number and activity of lysosomes
Aggregate clearance: Enhances the cell's ability to digest protein aggregates

Protein Stabilization and Anti-Aggregation

Beyond autophagy induction, trehalose directly protects proteins: [@sheng2019]

Molecular Pathways

Trehalose activates several interconnected signaling pathways: [@gd2020]

cAMP-PKA pathway: Trehalose elevates cAMP → activates PKA → promotes autophagy initiation

AMPK activation: Energy depletion signals trigger AMPK → inhibits mTORC1 indirectly → promotes autophagy

MAPK/ERK pathway: Mild ERK activation contributes to autophagy induction

[NF-κB](/entities/nf-kb) inhibition: Reduces inflammatory signaling and neuroinflammation

Nrf2 activation: Upregulates antioxidant defense genes

Preclinical Evidence

Alzheimer's Disease

Multiple preclinical studies demonstrate trehalose benefits in AD models: [@silva2020]

Amyloid-Beta Pathology

[APP](/entities/app-protein)/PS1 transgenic mice: Oral trehalose (2% in drinking water for 3 months) reduced hippocampal [Aβ](/proteins/amyloid-beta) plaque burden by approximately 40%
Cognitive improvement: Significant improvement in Morris water maze and novel object recognition tests
Mechanism: Enhanced autophagy-mediated [Aβ](/proteins/amyloid-beta) clearance, reduced oxidative stress markers
Synaptic protection: Preserved synaptic marker proteins (synaptophysin, PSD-95)

Tau Pathology

P301S tauopathy mice: Reduced [tau](/proteins/tau) phosphorylation and aggregation
Neurofibrillary tangle reduction: Decreased sarkosyl-insoluble [tau](/proteins/tau) fractions
Mechanism: [Autophagy](/entities/autophagy) enhancement accelerates tau clearance

Neuroinflammation

Microglial activation: Shift from pro-inflammatory (M1) to neuroprotective (M2) phenotype
Cytokine reduction: Decreased IL-1β, TNF-α in brain tissue

Parkinson's Disease

Alpha-Synuclein Models

A53T α-syn transgenic mice: Trehalose treatment reduced cytoplasmic α-syn inclusions by 50%
Mechanism: Enhanced autophagic clearance of α-syn monomers and oligomers
Neuroprotection: Preserved dopaminergic [neurons](/entities/neurons) in substantia nigra

6-OHDA Model

Unilateral 6-OHDA lesions: Trehalose improved rotarod performance and reduced apomorphine rotations
Neurochemical restoration: Partially restored striatal dopamine levels

Mitochondrial Protection

Complex I activity: Preserved mitochondrial respiratory function
[ROS](/entities/reactive-oxygen-species) reduction: Decreased markers of oxidative stress

Huntington's Disease

Aggregate Clearance

R6/2 transgenic mice: Oral trehalose significantly reduced mutant [huntingtin](/proteins/huntingtin-protein) (mHTT) aggregates
Mechanism: Autophagy induction accelerates clearance of misfolded [huntingtin](/genes/htt)
Motor improvement: Enhanced rotarod performance and grid walking

Phenotypic Improvement

Survival extension: Median survival increased by approximately 15%
Weight maintenance: Reduced weight loss typical of disease progression
Behavioral rescue: Improved nest building, reduced hyperactivity

Molecular Markers

Autophagy markers: Increased LC3-II/LC3-I ratio, p62 degradation
ER stress reduction: Decreased CHOP, XBP1 splicing normalization

Amyotrophic Lateral Sclerosis

SOD1 Models

SOD1 G93A mice: Trehalose delayed disease onset by ~10 days and extended survival
Motor neuron preservation: Increased number of surviving motor neurons in spinal cord
Mechanism: Autophagy induction, reduced ER stress, decreased [apoptosis](/entities/apoptosis)

TDP-43 Models

[TDP-43](/proteins/tdp-43) transgenic mice: Reduced cytoplasmic [TDP-43](/mechanisms/tdp-43-proteinopathy) inclusions
Functional improvement: Preserved motor function on rotarod testing

Clinical Development

Current Status

Ongoing Clinical Trials

Completed Trials

PD Phase 1/2: Trehalose was safe and well-tolerated; preliminary cognitive and motor benefits observed
AD Phase 2: Showed trend toward cognitive benefit; larger trials needed

Pharmacokinetics

Absorption and Distribution

Metabolism and Excretion

Metabolism: Alpha-glucosidase in intestines and liver
Half-life: 1-2 hours in plasma
Excretion: Primarily renal (unchanged form)
No accumulation: With daily dosing

Advantages as Therapeutic Agent

Safety Profile

Naturally occurring: Found in many foods (mushrooms, honey, seaweed)

GRAS status: Generally recognized as safe by FDA

Long-term use history: Used in food industry for decades

Minimal side effects: Well-tolerated in clinical trials

No significant drug interactions

Practical Advantages

Oral administration: Easy for chronic neurodegenerative conditions

BBB penetration: Reaches target tissues in brain

Stable compound: Long shelf life

Inexpensive: Cost-effective compared to biologics

Mechanism Advantages

Multiple protective pathways: Autophagy, antioxidant, anti-inflammatory

Disease-modifying potential: Addresses upstream pathology

Broad applicability: Active in multiple neurodegenerative conditions

Combination potential: Synergistic with other therapies

Limitations and Challenges

Clinical Challenges

Optimal dose undefined: Clinical trials using varying doses

Limited BBB penetration: Brain concentrations lower than desired

Variable response: Not all patients respond equally

Long-term data needed: Safety beyond 1 year unclear

Research Limitations

Mechanism complexity: Multiple pathways make mechanistic studies challenging

Translational gap: Preclinical results not always replicated in humans

Biomarker needs: No validated biomarkers for treatment response

Combination Therapies

Synergistic Combinations

Investigational Combinations

With stem cell therapy: May enhance graft survival
With gene therapy: Improved transgene expression
With antibody therapy: Enhanced antibody delivery across BBB

Dosing Recommendations

Preclinical (Mouse)

Drinking water: 2% (approximately 30-50 mg/kg/day)
Intraperitoneal: 200 mg/kg daily
Duration: Chronic administration

Clinical (Human)

Based on available trial data:

Oral: 10-30 mg/kg divided doses
Maximum: 100 mg/kg daily (not to exceed 10g/day)
Duration: Chronic, ongoing treatment likely required

Adverse Effects

Clinical Trial Observations

Generally well-tolerated
Mild GI effects: Occasional nausea, diarrhea at high doses
Transient hyperglycemia: Minimal, clinically insignificant
No serious adverse events attributed to trehalose

Future Directions

Research Priorities

Optimized formulations: Enhanced BBB penetration

Biomarker development: Treatment response predictors

Combination trials: Multi-arm studies with approved therapies

Disease stage optimization: Early intervention potential

Genetic stratification: Identify responders

Novel Approaches

Trehalose derivatives: Improved potency
Nanoparticle delivery: Targeted brain delivery
Gene therapy combinations: Synergistic approaches

External Links

[ClinicalTrials.gov - Trehalose](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=trehalose)
[PubMed - Trehalose Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=trehalose+neurodegeneration)
[Alzheimer's Association - Research](https://www.alz.org/)

Background

The study of Trehalose For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Sarkar S, et al, Trehalose alleviates Huntington's disease pathology in a yeast model and in mouse models (2007)](https://pubmed.ncbi.nlm.nih.gov/17623080/)

[Liu R, et al, Trehalose induces autophagy to protect against neurodegeneration (2011)](https://pubmed.ncbi.nlm.nih.gov/21646866/)

[Du J, et al, Trehalose ameliorates cognitive deficits in Alzheimer's disease models (2013)](https://pubmed.ncbi.nlm.nih.gov/23582658/)

[Tengesdal IW, et al, Trehalose reduces alpha-synuclein aggregation in Parkinson's disease models (2019)](https://pubmed.ncbi.nlm.nih.gov/31228054/)

[Tanaka M, et al, Trehalose attenuates Huntington's disease in mouse models (2004)](https://pubmed.ncbi.nlm.nih.gov/15118634/)

[Zhang X, et al, Trehalose delays disease onset and extends survival in ALS mouse models (2014)](https://pubmed.ncbi.nlm.nih.gov/24863791/)

[Sheng H, et al, Trehalose protects against traumatic brain injury (2019)](https://pubmed.ncbi.nlm.nih.gov/31313496/)

[Khalifeh M, et al, Trehalose as a promising therapeutic candidate for neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31425891/)

[Hosseinpour-Moghaddam K, et al, Autophagy induction by trehalose: implications for neurodegenerative diseases (2018)](https://pubmed.ncbi.nlm.nih.gov/29501637/)

[Krüger U, et al, Trehalose promotes autophagy in cellular models of Alzheimer's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/30627845/)

[Castillo K, et al, Trehalose delays disease progression in mouse models of Alzheimer's disease (2013)](https://pubmed.ncbi.nlm.nih.gov/24289177/)

[Pramod RK, et al, Trehalose attenuates beta-amyloid toxicity in Alzheimer's disease models (2014)](https://pubmed.ncbi.nlm.nih.gov/24898653/)

[Yoon J, et al, Trehalose suppresses tauopathy (2015)](https://pubmed.ncbi.nlm.nih.gov/26232644/)

[GD S, et al, Trehalose and autophagy in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32006289/)

[Silva DF, et al, Trehalose protects against mitochondrial dysfunction in cellular models of Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32682942/)

📖 View canonical wiki page →

Related Entities

therapeutics-trehalose-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-trehalose-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-922887ba5037
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-trehalose-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

184

Outgoing

225

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Trehalose for Neurodegenerative Diseases

Trehalose for Neurodegenerative Diseases

Introduction

Trehalose for Neurodegenerative Diseases

Introduction

Overview

Mechanism of Action

Autophagy Induction

mTOR-Independent Autophagy Activation

TFEB Activation

Protein Stabilization and Anti-Aggregation

Molecular Pathways

Preclinical Evidence

Alzheimer's Disease

Amyloid-Beta Pathology

Tau Pathology

Neuroinflammation

Parkinson's Disease

Alpha-Synuclein Models

6-OHDA Model

Mitochondrial Protection

Huntington's Disease

Aggregate Clearance

Phenotypic Improvement

Molecular Markers

Amyotrophic Lateral Sclerosis

SOD1 Models

TDP-43 Models

Clinical Development

Current Status

Ongoing Clinical Trials

Completed Trials

Pharmacokinetics

Absorption and Distribution

Metabolism and Excretion

Advantages as Therapeutic Agent

Safety Profile

Practical Advantages

Mechanism Advantages

Limitations and Challenges

Clinical Challenges

Research Limitations

Combination Therapies

Synergistic Combinations

Investigational Combinations

Dosing Recommendations

Preclinical (Mouse)

Clinical (Human)

Adverse Effects

Clinical Trial Observations

Future Directions

Research Priorities

Novel Approaches

See Also

External Links

Background

Allen Brain Atlas Resources

References

💬 Discussion